8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 30, 2026·SEC
HCW Biologics Inc.(HCWB)Earnings, Financials & Key Ratios
HCWB•NASDAQ
Price updated Jun 19, 2026
AboutHCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.Show more
- Revenue$54K-97.9%
- EBITDA-$10M+63.9%
- Net Income-$8M+73.5%
- EPS (Diluted)-10.63-1280.5%
- Gross Margin20%-46.5%
- EBITDA Margin-18836.7%-1608.8%
- Operating Margin-20757.65%-1707.4%
- Net Margin-14677.14%-1154.8%
- ROE-287.9%+67.9%
HCWB Key Insights
HCW Biologics Inc. (HCWB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 90 (top 10%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 94.6% through buybacks
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗High debt to equity ratio of 2.5x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 57.9% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HCWB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCWB Price & Volume
HCW Biologics Inc. (HCWB) stock price & volume — 10-year historical chart
Loading chart...
HCWB Growth Metrics
HCW Biologics Inc. (HCWB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-57.9%
3 Years-79.94%
TTM356.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM93.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1234.49%
Return on Capital
10 Years-161.17%
5 Years-199.32%
3 Years-308.03%
Last Year-553.87%
HCWB Peer Comparison
HCW Biologics Inc. (HCWB) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare HCWB vs Peers
HCW Biologics Inc. (HCWB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HCWB Income Statement
HCW Biologics Inc. (HCWB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 4.1M | 0 | 6.72M | 2.84M | 2.57M | 54.23K | 6.59M |
Revenue Growth % | - | - | -100% | - | -57.72% | -9.68% | -97.89% | 356.16% |
Cost of Goods Sold | 421.82K | 0 | 0 | 4.14M | 2.28M | 1.61M | 43.39K | 50.41K |
COGS % of Revenue | - | - | - | 61.52% | 80.28% | 62.62% | 80% | - |
Gross Profit | -421.82K▲ 0% | 4.1M▲ 1071.9% | 0▼ 100.0% | 2.59M▲ 0% | 560.36K▼ 78.3% | 959.4K▲ 71.2% | 10.85K▼ 98.9% | 6.54M▲ 0% |
Gross Margin % | - | 100% | - | 38.48% | 19.72% | 37.38% | 20% | 99.24% |
Gross Profit Growth % | - | 1071.93% | -100% | - | -78.33% | 71.21% | -98.87% | - |
Operating Expenses | 6.94M | 9.92M | 13.37M | 17.67M | 26.28M | 30.44M | 11.27M | 12.98M |
OpEx % of Revenue | - | 242.07% | - | 262.79% | 924.68% | 1185.88% | 20777.65% | - |
Selling, General & Admin | 1.8M | 2.44M | 4.98M | 7.99M | 13.08M | 21.95M | 7.7M | 7.29M |
SG&A % of Revenue | - | 59.42% | - | 118.84% | 460.43% | 854.97% | 14200.62% | - |
Research & Development | 5.14M | 7.26M | 8.17M | 9.34M | 7.68M | 6.39M | 5.44M | 5.22M |
R&D % of Revenue | - | 176.97% | - | 138.92% | 270.12% | 248.91% | 10036.3% | - |
Other Operating Expenses | 0 | 233.04K | 218.47K | 338.46K | 5.52M | 2.1M | -1.88M | 471.94K |
Operating Income | -7.37M▲ 0% | -5.82M▲ 20.9% | -13.37M▼ 129.5% | -15.08M▼ 12.8% | -25.72M▼ 70.6% | -29.48M▼ 14.6% | -11.26M▲ 61.8% | -6.45M▲ 0% |
Operating Margin % | - | -142.07% | - | -224.32% | -904.96% | -1148.5% | -20757.65% | -97.88% |
Operating Income Growth % | - | 20.92% | -129.51% | -12.8% | -70.55% | -14.63% | 61.81% | - |
EBITDA | -6.94M | -5.25M | -12.82M | -14.36M | -24.58M | -28.3M | -10.22M | -5.69M |
EBITDA Margin % | - | -128.1% | - | -213.64% | -865.02% | -1102.36% | -18836.7% | -86.28% |
EBITDA Growth % | - | 24.37% | -144.19% | -11.98% | -71.17% | -15.11% | 63.9% | 74.82% |
D&A (Non-Cash Add-back) | 421.82K | 572.87K | 543.6K | 717.85K | 1.14M | 1.18M | 1.04M | 764.81K |
EBIT | -7.29M | -5.82M | -12.86M | -14.77M | -24.71M | -28.87M | -6.71M | -1.83M |
Net Interest Income | 72.35K | 22.32K | 505.37K | -126.66K | -283.04K | -1.16M | -1.25M | -488.55K |
Interest Income | 72.35K | 22.32K | 505.37K | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 126.66K | 283.04K | 1.16M | 1.25M | 488.55K |
Other Income/Expense | 72.35K | 22.32K | 505.37K | 178.07K | 722.88K | -544.15K | 3.3M | 4.49M |
Pretax Income | -7.29M▲ 0% | -5.8M▲ 20.4% | -12.86M▼ 121.7% | -14.9M▼ 15.8% | -24.99M▼ 67.7% | -30.02M▼ 20.1% | -7.96M▲ 73.5% | -1.96M▲ 0% |
Pretax Margin % | - | -141.53% | - | -221.67% | -879.52% | -1169.7% | -14677.14% | -29.73% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -330.19K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 16.84% |
Net Income | -7.29M▲ 0% | -5.78M▲ 20.7% | -12.86M▼ 122.5% | -14.9M▼ 15.8% | -24.99M▼ 67.7% | -30.02M▼ 20.1% | -7.96M▲ 73.5% | -1.63M▲ 0% |
Net Margin % | - | -140.98% | - | -221.67% | -879.52% | -1169.7% | -14677.14% | -24.73% |
Net Income Growth % | - | 20.75% | -122.54% | -15.85% | -67.74% | -20.12% | 73.49% | 93.41% |
Net Income (Continuing) | -7.29M | -5.8M | -12.86M | -14.9M | -24.99M | -30.02M | -7.96M | -1.63M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.21▲ 0% | -0.16▲ 23.8% | -0.36▼ 125.0% | -0.42▼ 16.7% | -0.70▼ 66.7% | -0.77▼ 10.0% | -10.63▼ 1280.5% | -0.78▲ 0% |
EPS Growth % | - | 23.81% | -125% | -16.67% | -66.67% | -10% | -1280.52% | -1234.49% |
EPS (Basic) | -0.21 | -0.16 | -0.36 | -0.42 | -0.70 | -0.77 | -10.63 | - |
Diluted Shares Outstanding | 36.7M | 36.7M | 35.77M | 35.82M | 35.93M | 38.79M | 2.1M | 2.1M |
Basic Shares Outstanding | 36.7M | 36.7M | 35.77M | 35.82M | 35.93M | 38.79M | 2.1M | 2.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
HCWB Balance Sheet
HCW Biologics Inc. (HCWB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.03M | 12.15M | 40.48M | 34.07M | 6.4M | 5.7M | 2.28M | 1.72M |
Cash & Short-Term Investments | 7.36M | 8.46M | 36.71M | 32.06M | 3.6M | 4.67M | 1.95M | 1.23M |
Cash Only | 7.36M | 8.46M | 11.73M | 22.33M | 3.6M | 4.67M | 1.95M | 1.23M |
Short-Term Investments | 0 | 0 | 24.98M | 9.74M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 2.5M | 133K | 417.69K | 1.54M | 582.2K | 32.17K | 74.84K |
Days Sales Outstanding | - | 222.57 | - | 22.68 | 197.25 | 82.79 | 216.55 | 2.21 |
Inventory | 0 | 0 | 0 | 1.39M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | 123.11 | - | - | - | - |
Other Current Assets | 236.29K | 654.53K | 1.44M | 196.01K | 230.92K | 113.53K | 299.72K | 417.6K |
Total Non-Current Assets | 2.04M | 3.25M | 13.03M | 12.74M | 22.11M | 24.54M | 22.24M | 25.62M |
Property, Plant & Equipment | 2M | 1.62M | 1.12M | 10.8M | 20.45M | 22.91M | 20.88M | 20.77M |
Fixed Asset Turnover | - | 2.54x | - | 0.62x | 0.14x | 0.11x | 0.00x | 0.30x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 1.6M | 11.52M | 1.6M | 1.6M | 1.6M | 1.33M | 10.83M |
Other Non-Current Assets | 34.24K | 34.24K | 393.32K | 333.88K | 56.54K | 28.48K | 28.48K | 28.48K |
Total Assets | 10.07M▲ 0% | 15.4M▲ 53.0% | 53.51M▲ 247.5% | 46.81M▼ 12.5% | 28.51M▼ 39.1% | 30.24M▲ 6.0% | 24.52M▼ 18.9% | 27.34M▲ 0% |
Asset Turnover | - | 0.27x | - | 0.14x | 0.10x | 0.08x | 0.00x | 0.25x |
Asset Growth % | - | 52.97% | 247.54% | -12.53% | -39.09% | 6.04% | -18.91% | -11.28% |
Total Current Liabilities | 1.07M | 1M | 2.32M | 2.96M | 8.75M | 29.63M | 21.06M | 19.96M |
Accounts Payable | 392.33K | 155.34K | 223.66K | 1.23M | 6.17M | 22.33M | 13.14M | 11.79M |
Days Payables Outstanding | 339.49 | - | - | 108.22 | 986.68 | 5.07K | 110.57K | 114.51K |
Short-Term Debt | 0 | 567.31K | 0 | 0 | 0 | 6.31M | 6.81M | 6.58M |
Deferred Revenue (Current) | 0 | 0 | 1.8M | 0 | 0 | 0 | 0 | 470K |
Other Current Liabilities | 0 | 278.43K | 297.93K | 0 | 0 | 774.94K | 0 | 1.13M |
Current Ratio | 7.53x | 12.14x | 17.44x | 11.52x | 0.73x | 0.19x | 0.11x | 0.09x |
Quick Ratio | 7.53x | 12.14x | 17.44x | 11.05x | 0.73x | 0.19x | 0.11x | 0.09x |
Cash Conversion Cycle | - | - | - | 37.57 | - | - | - | -114.51K |
Total Non-Current Liabilities | 0 | 0 | 0 | 6.42M | 6.3M | 7.38M | 692.53K | 1.62M |
Long-Term Debt | 0 | 0 | 0 | 6.41M | 6.3M | 7.38M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 692.53K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 14.28K | 0 | 0 | 692.53K | 1.62M |
Total Liabilities | 1.07M | 1M | 2.32M | 9.38M | 15.05M | 37.01M | 21.76M | 21.58M |
Total Debt | 0 | 567.31K | 0 | 6.41M | 6.3M | 13.69M | 6.81M | 6.58M |
Net Debt | -7.36M | -7.89M | -11.73M | -15.92M | 2.71M | 9.02M | 4.86M | 5.35M |
Debt / Equity | - | 0.04x | - | 0.17x | 0.47x | - | 2.46x | 1.14x |
Debt / EBITDA | - | - | - | - | - | - | - | -1.16x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.94x |
Interest Coverage | - | - | - | -116.64x | -87.31x | -24.92x | -5.37x | -3.74x |
Total Equity | 9M▲ 0% | 14.4M▲ 60.0% | 51.19M▲ 255.6% | 37.43M▼ 26.9% | 13.46M▼ 64.0% | -6.77M▼ 150.3% | 2.76M▲ 140.8% | 5.76M▲ 0% |
Equity Growth % | - | 59.97% | 255.58% | -26.89% | -64.03% | -150.29% | 140.84% | 486.18% |
Book Value per Share | 0.25 | 0.39 | 1.43 | 1.04 | 0.37 | -0.17 | 1.32 | 2.75 |
Total Shareholders' Equity | 9M | 14.4M | 51.19M | 37.43M | 13.46M | -6.77M | 2.76M | 5.76M |
Common Stock | 472 | 1.12K | 3.58K | 3.59K | 3.6K | 4.45K | 328 | 673 |
Retained Earnings | -9.68M | -16.72M | -30.64M | -45.54M | -70.53M | -100.56M | -108.52M | -105.04M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HCWB Cash Flow Statement
HCW Biologics Inc. (HCWB) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.77M | -10.43M | -10.98M | -10.39M | -22.51M | -14.23M | -13.39M | -11.45M |
Operating CF Margin % | - | -254.44% | - | -154.51% | -792.25% | -554.29% | -24693.2% | - |
Operating CF Growth % | - | -54.19% | -5.22% | 5.37% | -116.77% | 36.81% | 5.87% | 58.59% |
Net Income | -7.29M | -5.8M | -12.86M | -14.9M | -24.99M | -30.02M | -7.96M | -1.63M |
Depreciation & Amortization | 421.82K | 572.87K | 543.6K | 717.85K | 1.14M | 1.18M | 1.04M | 764.81K |
Stock-Based Compensation | 1.76K | 21.88K | 360.98K | 1.12M | 1M | 1.01M | 768.62K | 297.51K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 23.04K | -473.22K | 188.46K | 4.98M | -418 | -4.46M | -8.57M |
Working Capital Changes | 104.17K | -5.25M | 1.46M | 2.49M | -4.64M | 13.6M | -2.78M | -1.65M |
Change in Receivables | 0 | -2.5M | 2.37M | -284.69K | -1.12M | 953.56K | 550.03K | 12.65K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 766.39K | -628.65K | 1.89M | 418.21K | 1.62M | 11.87M | -3.47M | -2.42M |
Cash from Investing | -1.46M | -186.68K | -35.02M | 14.71M | 3.8M | -261.62K | 0 | 0 |
Capital Expenditures | -1.46M | -186.68K | -47.26K | -10.28M | -6.2M | -261.62K | 0 | 0 |
CapEx % of Revenue | - | 4.55% | - | 152.86% | 218.26% | 10.19% | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 164 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 13.45M | 11.72M | 49.27M | 6.27M | -14.53K | 15.57M | 10.67M | 11.57M |
Debt Issued (Net) | 0 | 563.59K | 0 | 6.45M | -38.27K | 6.79M | 22.38K | -204.47K |
Equity Issued (Net) | 13.45M | 11.15M | 56.03M | 15.78K | 23.74K | 6.46M | 11.86M | 8.25M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -6.76M | -190.55K | 0 | 2.32M | -1.21M | 3.52M |
Net Change in Cash | 5.22M▲ 0% | 1.1M▼ 78.9% | 3.27M▲ 197.7% | 10.6M▲ 223.5% | -18.73M▼ 276.8% | 1.08M▲ 105.8% | -2.72M▼ 352.2% | 121.27K▲ 0% |
Free Cash Flow | -8.23M▲ 0% | -10.62M▼ 29.1% | -11.02M▼ 3.8% | -20.66M▼ 87.4% | -28.72M▼ 39.0% | -14.49M▲ 49.5% | -13.39M▲ 7.6% | -11.45M▲ 0% |
FCF Margin % | - | -258.99% | - | -307.36% | -1010.51% | -564.48% | -24693.2% | -173.74% |
FCF Growth % | - | -29.09% | -3.81% | -87.44% | -38.99% | 49.54% | 7.57% | 19.74% |
FCF per Share | -0.22 | -0.29 | -0.31 | -0.58 | -0.80 | -0.37 | -6.38 | -5.46 |
FCF Conversion (FCF/Net Income) | 0.93x | 1.80x | 0.85x | 0.70x | 0.90x | 0.47x | 1.68x | 7.03x |
Interest Paid | 0 | 0 | 0 | 126.66K | 283.04K | 569.77K | 0 | 159.89K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HCWB Key Ratios
HCW Biologics Inc. (HCWB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -49.41% | -39.22% | -33.63% | -98.23% | -897.37% | -287.9% | -102.39% |
Return on Invested Capital (ROIC) | -107.17% | -43.62% | -37.09% | -102.37% | -240.08% | -171.1% | -70.84% |
Gross Margin | 100% | - | 38.48% | 19.72% | 37.38% | 20% | 99.24% |
Net Margin | -140.98% | - | -221.67% | -879.52% | -1169.7% | -14677.14% | -24.73% |
Debt / Equity | 0.04x | - | 0.17x | 0.47x | - | 2.46x | 1.14x |
Interest Coverage | - | - | -116.64x | -87.31x | -24.92x | -5.37x | -3.74x |
FCF Conversion | 1.80x | 0.85x | 0.70x | 0.90x | 0.47x | 1.68x | 7.03x |
Revenue Growth | - | -100% | - | -57.72% | -9.68% | -97.89% | 356.16% |
Related:HCWB Dividend History·HCWB Revenue History·HCWB Price History·HCWB P/E History·HCWB Financial Ratios·HCWB Institutional Holders
HCWB SEC Filings & Documents
HCW Biologics Inc. (HCWB) SEC filings — annual & quarterly reports (10-K, 10-Q)
HCWB Frequently Asked Questions
HCW Biologics Inc. (HCWB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
HCW Biologics Inc. (HCWB) reported $6.6M in revenue for fiscal year 2025.
HCW Biologics Inc. (HCWB) saw revenue decline by 97.9% over the past year.
HCW Biologics Inc. (HCWB) reported a net loss of $1.6M for fiscal year 2025.
Dividend & Returns
HCW Biologics Inc. (HCWB) has a return on equity (ROE) of -287.9%. Negative ROE indicates the company is unprofitable.
HCW Biologics Inc. (HCWB) had negative free cash flow of $11.5M in fiscal year 2025, likely due to heavy capital investments.